Brokerages Set NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Price Target at $36.75

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been assigned a consensus rating of “Hold” from the six analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $36.75.

NRXP has been the topic of several recent research reports. Zacks Research cut NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. BTIG Research restated a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a research note on Thursday, January 15th. D. Boral Capital reaffirmed a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a research note on Monday, January 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th.

NRx Pharmaceuticals Price Performance

NASDAQ:NRXP opened at $2.12 on Tuesday. The business’s 50-day moving average is $2.31 and its two-hundred day moving average is $2.66. NRx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $3.84. The firm has a market capitalization of $62.75 million, a PE ratio of -0.90 and a beta of 1.62.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Friday, November 14th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $6.83 million. Equities analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Anson Funds Management LP raised its position in shares of NRx Pharmaceuticals by 26.2% in the 3rd quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock valued at $6,683,000 after purchasing an additional 420,129 shares in the last quarter. Vanguard Group Inc. raised its holdings in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after acquiring an additional 82,781 shares in the last quarter. AdvisorShares Investments LLC raised its holdings in NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after acquiring an additional 78,339 shares in the last quarter. Geode Capital Management LLC boosted its stake in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after acquiring an additional 37,598 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares in the last quarter. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.